VALBIOTIS SA: Valbiotis strengthens its financial resources to support the ramp-up of its commercial activity
16/11/2026 17:46Informations privilégiéesInformations réglementées continues
AMFImmediate publication
New non-dilutive bank financing from Société Générale, BNP Paribas and Bpifrance, and implementation of a factoring agreement
Valbiotis strengthens its financial resources to support the ramp-up of its commercial activity
New non-dilutive bank financing from Société Générale, BNP Paribas and Bpifrance, and implementation of a factoring agreement
La Rochelle, November 16, 2026 (5:40 PM CET) – Valbiotis (FR0013254851 – ALVAL, PEA/PME eligible), a French laboratory specializing in cardiometabolic health, announces new bank financing totaling €1.65M, as well as the signing of a factoring agreement with BNP Paribas Factor. These resources supplement the Company’s existing cash position and provide additional flexibility to support the ramp-up of its commercial activity, without dilution for its shareholders. Granted by its two longstanding banks and by Bpifrance, this financing demonstrates Valbiotis’ ability to mobilize leading financial partners in support of its development.
Sébastien Peltier, Chairman of the Management Board of Valbiotis, states: “The renewed confidence of our long-standing banking partners and Bpifrance is a strong signal. It illustrates our ability to secure financing tailored to each stage of our development. These resources supplement our cash position and give us the means to support, under the best possible conditions, the ramp-up of our sales, particularly in pharmacies.”
Three loans totaling €1.65M
Valbiotis has obtained three non-dilutive loans, all at fixed rates:
- two loans of €600K each, with a 4-year term, granted by its two long-standing banking partners, Société Générale and BNP Paribas;
- one loan of €450K granted by Bpifrance, with a total term of 8 years, including a 3-year repayment deferral followed by a 5-year amortization period.
A factoring agreement to support commercial growth in pharmacies
In parallel, Valbiotis has signed a factoring agreement (trade receivables financing) with BNP Paribas Factor, with a total authorized funding limit of €500K, which may be increased at any time during the Press release term of the agreement in line with business growth. This facility is intended to finance the working capital requirement related to trade receivables, which is expected to grow with the anticipated ramp-up of revenue in the pharmacy channel, where payment terms are 45 days end of month.
Resources that supplement the Company’s cash position and strengthen
Valbiotis’ financing capacity
This financing comes in addition to the €11.7M in cash held by Valbiotis as of June 30, 2026, which provides the Company with a cash runway through the end of 2027, excluding any additional sources of financing. By dedicating specific instruments to financing its growth – amortizing loans and trade receivables factoring – Valbiotis strengthens its financial flexibility and can allocate its resources as a priority to the commercial rollout of its products, without dilution for its shareholders. Beyond the amounts involved, this financing is a sign of confidence: the renewed support of its two longstanding banks, alongside Bpifrance, illustrates the lasting relationship Valbiotis has built with its financial partners and its ability to mobilize diversified resources tailored to each stage of its development.